OSE_1309_part2_Layout 1 9/6/13 12:23 PM Page 85
For the Management of Postsurgical Pain
EXPAREL® (bupivacaine liposome injectable suspension)
Patient-Focused
Pain Control That
Lasts For Up
To 72 Hours
The only single-dose local analgesic to
Reduce or eliminate opioids with pain control
for up to 3 days
Without the need for catheters or pumps
Pivotal studies have demonstrated the safety and efficacy of EXPAREL in patients undergoing bunionectomy and
hemorrhoidectomy procedures.
The clinical benefit of the attendant decrease in opioid consumption was not demonstrated.
EXPAREL is a liposome formulation of bupivacaine indicated for administration into the surgical site to produce
postsurgical analgesia.
Important Safety Information:
EXPAREL is contraindicated in obstetrical paracervical block anesthesia. EXPAREL has not been studied for use in
patients younger than 18 years of age. Non-bupivacaine-based local anesthetics, including lidocaine, may cause an
immediate release of bupivacaine from EXPAREL if administered together locally. The administration of EXPAREL
may follow the administration of lidocaine after a delay of 20 minutes or more. Other formulations of bupivacaine
should not be administered within 96 hours following administration of EXPAREL. Monitoring of cardiovascular
and neurological status, as well as vital signs should be performed during and after injection of EXPAREL as with
other local anesthetic products. Because amide-type local anesthetics, such as bupivacaine, are metabolized
by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with severe hepatic
disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic
plasma concentrations. In clinical trials, the most common adverse reactions (incidence ≥10%) following EXPAREL
administration were nausea, constipation, and vomiting.
Reference: Gorfine SR, et al. Dis Colon Rectum. Dec 2011;54(12):1552-1559.
Please see brief summary of Prescribing Information on reverse side.
For more information, visit www.EXPAREL.com
©2013 Pacira Pharmaceuticals, Inc., Parsippany, NJ 07054
EXP-AP-0039-201302
